The Murine C′-Terminally Alternatively Spliced Form of p53 Induces Attenuated Apoptosis in Myeloid Cells

REFERENCES

• Alexander, W. S., S. D. Lyman, and E. F. Wagner. 1991. Expression of functional c-kit receptors rescues the genetic defect of the W mutant mast cells. EMBO J. 10:3683–3691.
   PubMed Web of Science ®Google Scholar
• Aloni-Grinstein, R., D. Schwartz, and V. Rotter. 1995. Accumulation of wild type p53 protein upon μ-irradiation induces a G2-dependent immunoglobulin n light chain gene expression. EMBO J. 14:1392–1401.
   PubMedGoogle Scholar
• Arai, N., D. Nomura, K. Yokota, D. Wolf, E. Brill, O. Shohat, and V. Rotter. 1986. Immunologically distinct p53 molecules generated by alternative splicing. Mol. Cell. Biol. 6:3232–3239.
   PubMedGoogle Scholar
• Bargonetti, J., J. J. Manfredi, X. Chen, D. R. Marshak, and C. Prives. 1993. A proteolytic fragment from the central region of p53 has marked sequencespecific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev. 7:2565–2574.
   PubMed Web of Science ®Google Scholar
• Bayle, J. H., B. Elenbaas, and A. J. Levine. 1995. The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. Proc. Natl. Acad. Sci. USA 92:5729–5733.
   PubMed Web of Science ®Google Scholar
• Belloc, F., P. Dumain, M. R. Boisseau, C. Jalloustre, J. Reiffers, P. Bernard, and F. Lacombe. 1994. A flow cytometric method using Hoechst 33342 and propidium iodide for simultaneous cell cycle analysis and apoptosis determination in unfixed cells. Cytometry 17:59–65.
   PubMedGoogle Scholar
• Cho, Y., S. Gorina, P. D. Jeffrey, and N. P. Pavletich. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346–355.
   PubMed Web of Science ®Google Scholar
• Clore, G. M., J. G. Omichinski, K. Sakaguchi, N. Zambrano, H. Sakamoto, E. Appella, and A. M. Gronenborn. 1994. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science 265:386–394.
   PubMedGoogle Scholar
• Cross, S. M., C. A. Sanchez, C. A. Morgan, M. K. Schimke, S. Ramel, R. L. Idzerda, W. H. Raskind, and B. J. Reid. 1995. A p53-dependent mouse spindle checkpoint. Science 267:1353–1356.
   PubMed Web of Science ®Google Scholar
• Darzynkiewicz, Z., X. Li, and J. Gong. 1994. Assays of cell viability: discrimination of cell dying by apoptosis. Methods Cell Biol. 41:15–38.
   PubMed Web of Science ®Google Scholar
• Diller, L., J. Kassel, C. E. Nelson, M. A. Gryka, G. Litwak, M. Gebhardt, B. Bressac, M. Ozturk, S. J. Baker, B. Vogelstein, and S. H. Friend. 1990. p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol. 10:5772–5781.
   PubMed Web of Science ®Google Scholar
• Dulic, V., W. K. Kaufmann, S. J. Wilson, T. D. Tlsty, E. Lees, J. W. Harper, S. J. Elledge, and S. I. Reed. 1994. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation induced G1 arrest. Cell 76:1013–1023.
   PubMed Web of Science ®Google Scholar
• Dutta, A., J. M. Ruppert, J. C. Aster, and E. Wincherester. 1993. Inhibition of DNA replication factor RPA by p53. Nature 365:79–82.
   PubMed Web of Science ®Google Scholar
• Eastman, A. 1995. Assays for DNA fragmentation, endonucleases, and intracellular pH and Ca2+ associated with apoptosis. Methods Cell Biol. 46:41–55.
   PubMedGoogle Scholar
• El-Deiry, W. S., J. W. Harper, P. M. O’Connor, V. E. Velculescu, C. E. Canman, J. Jackman, J. A. Pietenpol, M. Burrell, D. E. Hill, and Y. Wang. 1994. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:1169–1174.
   PubMed Web of Science ®Google Scholar
• El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825.
   PubMed Web of Science ®Google Scholar
• El-Deiry, W. S., S. E. Kern, J. A. Pietenpol, K. W. Kinzler, and B. Vogelstein. 1992. Definition of a consensus binding site for p53. Nat. Genet. 1:45–49.
   PubMed Web of Science ®Google Scholar
• Fields, S., and S. K. Jang. 1990. Presence of potent transcription activating sequences in the p53 protein. Science 249:1046–1049.
   PubMed Web of Science ®Google Scholar
• Flaman, J.-M., F. Waridel, A. Estreicher, A. Vannier, J.-M. Limacher, D. Gilbert, R. Iggo, and T. Frebourg. 1996. The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene 12:813–818.
   PubMed Web of Science ®Google Scholar
• Ford, J. M., and P. C. Hanawalt. 1995. Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV-resistance. Proc. Natl. Acad. Sci. USA 92:8876–8890.
   PubMed Web of Science ®Google Scholar
• Gannon, J. V., R. Greaves, R. Iggo, and D. P. Lane. 1990. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 9:1595–1602.
   Google Scholar
• Gottlieb, E., R. Haffner, T. von Ruden, E. F. Wagner, and M. Oren. 1994. Down-regulation of wild type p53 activity interferes with apoptosis of IL-3- dependent hematopoietic cells following IL-3 withdrawal. EMBO J. 13:1368–1374.
   PubMed Web of Science ®Google Scholar
• Guillouf, C., X. Grana, M. Selvakumaran, A. De Luca, A. Giordano, B. Hoffman, and D. Liebermann. 1995. Dissection of genetic programs of p53- mediated G1 growth arrest and apoptosis: blocking p53-induced apoptosis unmasks G1 arrest. Blood 85:2691–2698.
   PubMed Web of Science ®Google Scholar
• Han, K., and M. F. Kulesz-Martin. 1992. Alternatively spliced p53 RNA in transformed and normal cells of different tissue types. Nucleic Acids Res. 20:1979–1981.
   PubMedGoogle Scholar
• Harlow, E., L. V. Crawford, D. C. Pim, and N. M. Williamson. 1981. Monoclonal antibodies specific for simian virus 40 tumor antigen. J. Virol. 39:861–869.
   PubMed Web of Science ®Google Scholar
• Haupt, Y., S. Rowan, E. Shaulian, K. H. Vousden, and M. Oren. 1995. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev. 9:2170–2183.
   PubMed Web of Science ®Google Scholar
• Hunter, T. 1993. Braking the cycle. Cell 75:839–841.
   PubMed Web of Science ®Google Scholar
• Hupp, T. R., D. W. Meek, C. A. Midgley, and D. P. Lane. 1992. Regulation of the specific DNA binding function of p53. Cell 71:875–886.
   PubMed Web of Science ®Google Scholar
• Hupp, T. R., D. W. Meek, C. A. Midgley, and D. P. Lane. 1993. Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res. 21:3167–3174.
   PubMed Web of Science ®Google Scholar
• Jayaraman, L., and C. Prives. 1995. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81:1021–1029.
   PubMed Web of Science ®Google Scholar
• Kastan, M. B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R. W. Craig. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304–6311.
   PubMed Web of Science ®Google Scholar
• Kastan, M. B., Q. Zhan, W. S. El-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunket, B. Vogelstein, and A. J. Fornace. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587–597.
   PubMed Web of Science ®Google Scholar
• Kuerbitz, S. J., B. S. Plunkett, W. V. Walsh, and M. B. Kastan. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89:7491–7495.
   PubMed Web of Science ®Google Scholar
• Kulesz-Martin, M. F., B. Lisafeld, H. Huang, N. D. Kisiel, and L. Lee. 1994. Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells. Mol. Cell. Biol. 14:1698–1708.
   PubMedGoogle Scholar
• Lane, D. P. 1992. p53, guardian of the genome. Nature 358:15–16.
   PubMed Web of Science ®Google Scholar
• Lee, S., B. Elenbaas, A. Levine, and J. Griffith. 1995. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/ deletion mismatches. Cell 81:1013–1020.
   PubMedGoogle Scholar
• Leveillard, T., L. Andera, N. Bissonnette, L. Schaeffer, L. Bracco, J. Egly, and B. Wasylyk. 1996. Functional interactions between p53 and the THIIH complex are affected by tumour-associated mutations. EMBO J. 15:1615–1624.
   PubMedGoogle Scholar
• Livingstone, L. R., A. White, J. Sprouse, E. Livanos, T. Jacks, and T. D. Tlsty. 1992. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923–935.
   PubMed Web of Science ®Google Scholar
• Lu, X., and D. P. Lane. 1993. Differential induction of transcriptionally active p53 following UV or ionizing irradiation: defects in chromosome instability syndromes? Cell 75:765–778.
   PubMed Web of Science ®Google Scholar
• Maltzman, W., and L. Czyzyk. 1984. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4:1689–1694.
   PubMed Web of Science ®Google Scholar
• Markowitz, D., S. Goff, and A. Bank. 1988. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J. Virol. 62:1120–1124.
   PubMed Web of Science ®Google Scholar
• Mercer, W. E., M. T. Shields, M. Amin, G. J. Sauve, E. Appella, J. W. Romano, and S. J. Ullrich. 1990. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild type p53. Proc. Natl. Acad. Sci. USA 87:6166–6170.
   PubMed Web of Science ®Google Scholar
• Michalovitz, D., O. Halevy, and M. Oren. 1990. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62:671–680.
   PubMed Web of Science ®Google Scholar
• Milne, D. M., R. H. Palmer, D. G. Campbell, and D. W. Meek. 1992. Phosphorylation of the p53 tumor-suppressor protein at three N terminal sites by a novel casein-kinase 1-like enzyme. Oncogene 7:1361–1370.
   PubMed Web of Science ®Google Scholar
• Milner, J., E. A. Medcalf, and A. C. Cook. 1991. Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol. Cell. Biol. 11:12–19.
   PubMed Web of Science ®Google Scholar
• Miyashita, T., S. Krajewski, M. Krajewska, H. G. Wang, H. K. Lin, and D. A. Liebermann. 1994. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799–1805.
   PubMed Web of Science ®Google Scholar
• Okamoto, K., and D. Beach. 1994. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J. 13:4816–4822.
   PubMed Web of Science ®Google Scholar
• Oltvai, Z. N., and S. J. Korsmeyer. 1994. Checkpoints of dueling dimers foil death wishes. Cell 79:189–192.
   PubMed Web of Science ®Google Scholar
• Oren, M. 1994. Relationship of p53 to the control of apoptotic cell death. Semin. Cancer Biol. 5:221–227.
   PubMed Web of Science ®Google Scholar
• O’Rourke, R. W., C. W. Miller, G. J. Kato, K. J. Simon, D.-L. Chen, C. V. Dang, and H. P. Koeffler. 1990. A potential transcriptional activation element in the p53 protein. Oncogene 5:1829–1832.
   PubMedGoogle Scholar
• Pavletich, N. P., K. A. Chambers, and C. O. Pabo. 1993. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 7:2556–2564.
   PubMed Web of Science ®Google Scholar
• Peled, A., B. C. Lee, J. Toledo, M. Aracil, and D. Zipori. 1996. Interactions between leukemia cells and bone marrow stromal cells: stroma-supported growth vs. serum dependence and the roles of TGF-b and M-CSF. Exp. Hematol. 24:728–737.
   PubMedGoogle Scholar
• Peled, A., D. Zipori, and V. Rotter. 1996. Cooperation between p53-dependent and p53-independent apoptotic pathways of myeloid cells. Cancer Res. 56:2148–2156.
   PubMed Web of Science ®Google Scholar
• Raycroft, L., H. Wu, and G. Lozano. 1990. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249:1049–1051.
   PubMed Web of Science ®Google Scholar
• Reed, M., B. Woelker, P. Wang, Y. Wang, M. E. Anderson, and P. Tegtmeyer. 1995. The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc. Natl. Acad. Sci. USA 92:9455–9459.
   PubMed Web of Science ®Google Scholar
• Ronen, D., D. Schwartz, Y. Teitz, N. Goldfinger, and V. Rotter. 1996. Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild type p53 protein whereas their differentiation is mediated by lower p53 levels. Cell Growth Differ. 7:21–30.
   PubMedGoogle Scholar
• Rotter, V., R. Aloni-Grinstein, D. Schwartz, N. B. Elkind, A. Simons, R. Wolkowicz, M. Lavigne, P. Besserman, A. Kapon, and N. Goldfinger. 1994. Does wild type p53 play a role in normal cell differentiation? Semin. Cancer Biol. 5:229–236.
   PubMed Web of Science ®Google Scholar
• Ryan, J. J., R. Danish, C. A. Gottlieb, and M. F. Clarke. 1993. Cell cycle analysis of p53-induced cell death in murine erythroleukemia cells. Mol. Cell. Biol. 13:711–719.
   PubMed Web of Science ®Google Scholar
• Shaulian, E., I. Haviv, Y. Shaul, and M. Oren. 1994. Transcriptional repression by the C-terminal domain of p53. Oncogene 10:671–680.
   Google Scholar
• Shaulsky, G., N. Goldfinger, A. Peled, and V. Rotter. 1991. Involvement of wild type p53 in pre-B cell differentiation in vitro. Proc. Natl. Acad. Sci. USA 88:8982–8986.
   PubMedGoogle Scholar
• Shaw, P., J. Freeman, R. Bovey, and R. Iggo. 1996. Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Oncogene 12:921–930.
   PubMed Web of Science ®Google Scholar
• Shohat-Foord, O., P. Bhattacharya, Z. Reich, and V. Rotter. 1991. A DNA binding domain is contained in the C-terminus of wild type p53 protein. Nucleic Acids Res. 19:5191–5198.
   PubMedGoogle Scholar
• Slingerland, J. M., J. R. Jenkins, and S. Benchimol. 1993. The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. EMBO J. 12:1029–1037.
   PubMed Web of Science ®Google Scholar
• Smith, M. L., I.-T. Chen, Q. Zhan, I. Bae, C.-Y. Chen, T. M. Glimer, M. B. Kastan, P. M. O’Connor, and J. A. J. Fornace. 1994. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266:1376–1378.
   PubMed Web of Science ®Google Scholar
• Stewart, N., G. G. Hicks, F. Paraskevas, and M. Mowat. 1994. Evidence for a second cell cycle block at G2/M by p53. Oncogene 10:109–115.
   Google Scholar
• Tarunina, M., and J. R. Jenkins. 1993. Human p53 binds DNA as a protein homodimer but monomeric variants retain full transcription transactivation activity. Oncogene 8:3165–3173.
   PubMedGoogle Scholar
• Vogelstein, B., and K. W. Kinzler. 1992. p53 function and dysfunction. Cell 70:523–526.
   PubMed Web of Science ®Google Scholar
• Wade-Harper, J., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805–816.
   PubMedGoogle Scholar
• Wang, X. W., K. Forrester, H. Yeh, M. A. Feitelson, J. Gu, and C. Harris. 1994. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. USA 91:2230–2234.
   PubMed Web of Science ®Google Scholar
• Wang, X. W., W. Vermeulen, J. D. Coursen, M. Gibson, S. E. Lupold, K. Forrester, G. Xu, L. Elmore, H. Yeh, J. H. J. Hoeijmakers, and C. C. Harris. 1996. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev. 10:1–14.
   PubMedGoogle Scholar
• Wang, X. W., H. Yeh, L. Schaeffer, R. Roy, V. Moncolli, J.-M. Egly, Z. Wang, E. C. Friedberg, M. K. Evans, B. G. Taffe, V. A. Bohr, G. Weeda, J. H. J. Hoeijmakers, K. Forrester, and C. C. Harris. 1995. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat. Genet. 10:188–195.
   PubMed Web of Science ®Google Scholar
• Wang, Y., M. Reed, P. Wang, J. E. Stenger, G. Mayr, M. E. Anderson, J. F. Schwedes, and P. Tegtmeyer. 1993. p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes Dev. 7:2575–2586.
   PubMedGoogle Scholar
• Will, K., G. Warnecke, S. Bergmann, and W. Deppert. 1995. Species- and tissue-specific expression of the C-terminal alternatively spliced form of the tumor suppressor p53. Nucleic Acids Res. 23:4023–4028.
   PubMedGoogle Scholar
• Williams, G. T. 1991. Programmed cell death: apoptosis and oncogenesis. Cell 65:1097–1098.
   PubMed Web of Science ®Google Scholar
• Wolf, D., N. Harris, N. Goldfinger, and V. Rotter. 1985. Isolation of full-length mouse cDNA clone coding for an immunologically distinct p53 molecule. Mol. Cell. Biol. 5:127–132.
   PubMedGoogle Scholar
• Wolkowicz, R., A. Peled, N. B. Elkind, and V. Rotter. 1995. The augmented DNA binding activity of an alternative spliced C′-terminal p53 is blocked by regular spliced p53 protein. Proc. Natl. Acad. Sci. USA 92:6842–6846.
   PubMedGoogle Scholar
• Wu, L., J. H. Bayle, B. Elenbaas, N. P. Pavletich, and A. J. Levine. 1995. Alternatively spliced forms in the carboxy-terminal domain of the p53 protein regulate its ability to promote annealing of complementary single strands of nucleic acids. Mol. Cell. Biol. 15:497–504.
   PubMedGoogle Scholar
• Wu, Y., Y. Liu, L. Lee, Z. Miner, and M. Kulesz-Martin. 1994. Wild-type alternatively spliced p53: binding to DNA and interaction with the major p53 protein in vitro and in cells. EMBO J. 13:4823–4830.
   PubMedGoogle Scholar
• Wyllie, A. H. 1995. The genetic regulation of apoptosis. Curr. Opin. Genet. Dev. 5:97–104.
   PubMed Web of Science ®Google Scholar
• Yewdell, J. W., J. V. Gannon, and D. P. Lane. 1986. Monoclonal antibody analysis of p53 expression in normal and transformed cells. J. Virol. 59:444–452.
   PubMed Web of Science ®Google Scholar
• Yin, Y., M. A. Tainsky, F. Z. Bischoff, L. C. Strong, and G. M. Wahl. 1992. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937–948.
   PubMed Web of Science ®Google Scholar
• Yonish-Rouach, E., V. Deguin, T. Zaitchouk, C. Breugnot, Z. Mishal, J. R. Jenkins, and E. May. 1996. Transcriptional activation plays a role in the induction of apoptosis by transiently transfected wild-type p53. Oncogene 12:2197–2205.
   Google Scholar
• Yonish-Rouach, E., D. Grunwald, S. Wilder, A. Kimchi, E. May, J.-J. Lawrence, P. May, and M. Oren. 1993. p53-mediated cell death: relationship to cell cycle control. Mol. Cell. Biol. 13:1415–1423.
   PubMed Web of Science ®Google Scholar
• Yonish-Rouach, E., K. Resnitzky, J. Lotem, L. Sachs, A. Kimchi, and M. Oren. 1991. Wild type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin 6. Nature 352:345–347.
   PubMed Web of Science ®Google Scholar
• Zauberman, A., A. Lupo, and M. Oren. 1995. Identification of p53 target genes through immune selection of genomic DNA: the cyclin G gene contains two distinct p53 binding sites. Oncogene 10:2361–2366.
   PubMedGoogle Scholar